FMP

FMP

Enter

ETNB - 89bio, Inc...

photo-url-https://images.financialmodelingprep.com/symbol/ETNB.png

89bio, Inc.

ETNB

NASDAQ

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

6.75 USD

0.17 (2.52%)

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

181.64M

121.07M

107.55M

149.9M

153.64M

152.62M

151.61M

150.61M

149.61M

148.63M

Operating Cash Flow

-

-

-

-

-

-

-

-

-

-

Cap Ex

-

-

-

-

-

-

-

-

-

-

Free Cash Flow

-

-

-

-

-

-

-

-

-

-

Wacc

8.78

8.78

8.78

8.78

8.78

Pv Lfcf

-

-

-

-

-

Sum Pv Lfcf

-

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep